Faculty

Needs Statement

Medication treatment for Opioid Use Disorder remains poorly understood such that few affected individuals ever receive these effective FDA-approved medications.

Providers need to know how treatment helps save lives and how they can identify and link patients to treatment.

Target Audience

This activity is designed for prescribers of controlled substances including physicians, nurse practitioners, and dentists and any other interested health care professionals.

Objectives

Upon completion of this educational activity, participants will be able to:

• Describe what an OUD is
• Describe its prevalence and risk factors and the role of FDA-approved medication in its treatment
• Explain the mechanisms of action for effective medication treatment of opioid use disorder

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Kentucky Office of Drug Control Policy. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1.

ACGME Competencies

• Patient care
• Medical knowledge

Other
UK Healthcare CECentral certifies this activity for 1.25 hours of participation.

CDE
This online course meets regulatory requirements for 1.25 hours credit as permitted by 201 KAR 8:532 for dentists and 201 KAR 8:562 for dental hygienists.

Faculty Disclosure

Michelle Lofwall, MD, speaker, has relevant financial relationships with commercial interests as follows:

• Researcher - NIH - Research Funding
• Consultant - Titan - Consultant Fee

No planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

 

Acknowledgement

This activity is jointly provided by the University of Kentucky and Kentucky Office of Drug Control Policy.

In collaboration with Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

• The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
• If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
• Issues regarding activity content also will be reviewed and addressed by the Activity Director.
• A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
• Grievances will be considered when planning future activities.

Appeal Procedure

• Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
• The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
• The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.